Sale

Generic Injectables Market

Global Generic Injectables Market Size, Share, Analysis: By Product Type: Large Molecule Injectables, Small Molecule Injectables; By Container Type: Vials, Premix, Prefilled Syringes, Ampoules, Others; By Application: Oncology, Others; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Generic Injectables Market Size

The global generic injectables market was valued at USD 56.9 billion in 2023, driven by rising healthcare needs and the introduction of supportive regulatory policies across the globe. The market is expected to grow at a CAGR of 7.80% during the forecast period of 2024-2032, with the values likely to rise from USD 61.6 billion to USD 112.2 billion by 2032.

 

Global Generic Injectables Market Outlook

  • The market is witnessing a surge in drug approvals of generic injectables by health regulatory agencies. For instance, in April 2024, Gland Pharma Limited received FDA approval for its generic Eribulin Mesylate Injection to treat breast cancer.
  • Recent market trends reveal consolidation via mergers and acquisitions among the key companies to boost market share and expand product portfolios.
  • The oncology segment covers a significant market share due to the rising burden of cancer, which increases the demand for chemotherapy treatments that often require generic injectables.

 

Global Generic Injectables Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Generic Injectables Market Overview

Generic injectables are similar to their brand-name counterparts in terms of active ingredients, clinical performance, and intended use, among others. They are administered generally through intramuscular or intravenous routes. Generic injectables offer a faster therapeutic effect, higher bioavailability, and can be formulated for slow and sustained release. The rising patent expiration of branded drugs is boosting the market entry of their generic versions, which are typically lower in price and show similar efficacy and safety profiles. The increasing prevalence of chronic diseases and the growing aging population significantly contribute to the rising market demand for generic injectables. Further, supportive policies and initiatives by the government also fuel the market growth by encouraging the use of generic drugs and ensuring faster approval processes for first-time generics.

 

Global Generic Injectables Market Growth Drivers

Surge in Drug Approvals of Generic Injectables to Affect the Market Landscape Significantly

The market is witnessing a surge in drug approvals of generic injectables by health regulatory agencies such as the United States Food and Drug Corporation (FDA). For instance, in April 2024, an India-based generic injectable manufacturer Gland Pharma Limited received FDA approval for its generic Eribulin Mesylate Injection (0.5 mg/mL single-dose vial) to treat breast cancer. The product, which Gland Pharma co-developed with a research-oriented pharmaceutical product development company Orbicular Pharmaceutical Technologies Private Ltd, is expected to be the first generic intravenous drug for this condition in the United States. The rise in approval of new generic injectables, accelerated by the presence of a supportive regulatory framework, is anticipated to influence the market dynamics.

 

Launch of New Products to Meet Rising Generic Injectables Market Demand

In March 2024, Meitheal Pharmaceuticals, Inc., a generic injectables company based in Chicago, announced recent business progress to support a sustainable drug supply in the United States following its generic injectables portfolio expansion in September 2023. The company is preparing to launch up to 20 new products in 2024 spread across various therapeutic areas and has invested over USD 100 million in generic research and development over the past six years. Additionally, the generic injectables manufacturer recently launched multiple presentations of bupivacaine hydrochloride injection (an anesthetic used for surgical, therapeutic, diagnostic, and obstetrical procedures). The rising introduction of sustainably manufactured and priced generic injectables is poised to augment market demand.

 

Generic Injectables Market by Container

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Generic Injectables Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

 

Key Trends Impact
Rising Technological Advancements in Manufacturing Processes The rising advancements in technology are allowing manufacturers to improve the efficiency and scalability of generic injectable production. Integration of innovations such as automation and data analytics in manufacturing processes helps in reduce costs and enhance quality control. This leads to the development of more reliable and consistent products, enabling companies to meet stringent regulatory standards and contributing to the overall market growth.
Increased Strategic Mergers and Acquisitions Recent market trends reveal consolidation via mergers and acquisitions among the key companies to boost market share and expand product portfolios. This strategy enables companies to enter new markets, optimize their supply chains, and increase R&D capabilities by sharing resources and expertise. Such strategic partnerships drive innovation and also elevate the generic injectables market value.
Growing Focus on Sterile Injectables The increasing focus on sterile injectables is in response to the need for higher safety standards in medication administration. This trend has led to substantial investments in cleanroom technology and quality control systems. The growing emphasis on sterile injectables is likely to improve patient safety and increase the demand for generic injectables in clinical settings.
Expansion into Emerging Markets Many generic injectables manufacturers are increasingly expanding their presence into emerging markets such as Asia, Latin America, and Africa. These regions offer significant growth opportunities due to rising healthcare needs and increasing investment in healthcare infrastructure. The rising introduction of international companies in these emerging economies is poised to increase access to affordable injectables in underserved areas, thereby contributing to improved patient outcomes.

 

Global Generic Injectables Market Segmentation

Market Breakup by Product Type

  • Large Molecule Injectables
    • Monoclonal Antibodies (mAbs)
    • Insulin
    • Others
  • Small Molecule Injectables

 

Market Breakup by Container Type

  • Vials
  • Premix
  • Prefilled Syringes
  • Ampoules
  • Others

 

Market Breakup by Application

  • Oncology
  • Cardiovascular
  • CNS
  • Infectious Diseases
  • Autoimmune Disorders
  • Others

 

Market Breakup by Route of Administration

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Others

 

Market Breakup by Distribution Channel

  • Hospital
  • Retail Pharmacy
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global Generic Injectables Market Share

Oncology Segment Leads Market Share by Application

Based on the application, the market is segmented into oncology, cardiovascular, CNS, infectious diseases, and autoimmune disorders, among others. The oncology segment covers a significant market share due to the rising burden of cancer, which increases the demand for chemotherapy treatments that often require generic injectables. Generic carboplatin and cisplatin are platinum-based, injectable chemotherapeutic drugs that are commonly used in curative regimens and combination therapies. Further, cardiovascular and Infectious segments also hold a high market value owing to its efficacy and rapid onset of action of various generic injectables in treating cardiovascular conditions and infectious diseases.

 

Market Segmentation Based on Container Type is Anticipated to Witness Substantial Growth

Container types available in the market include vials, premix, prefilled syringes, and ampoules, among others. The market share is driven by the rising need for reliable and cost-effective containers that are compatible with a wide range of drug formulations. Vial is the traditional container type and is commonly used due to its affordability, particularly for high-volume production. Additionally, the ease of manufacture and the simplicity of design make it a preferred choice for many pharmaceutical companies.

 

Generic Injectables Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Generic Injectables Market Analysis by Region

Based on the region, the market covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, with each region contributing to the overall dynamics of the market. North America holds the largest market share, valued at USD 33 billion in 2023, which can be attributed to the increasing burden of chronic diseases and the growing aging population. For instance, the American Cancer Society’s annual cancer statistics report estimated that new cancer cases will surpass 2 million in the United States in 2024, which indicates the need for effective and affordable generic drugs including generic injectables.

 

Europe also holds a high market value, with the market size estimated to be USD 13.5 billion in 2023, owing to the rising healthcare needs and the presence of a favorable regulatory environment. Asia Pacific is projected to witness exponential growth driven by increased government initiatives that promote the uptake and manufacture of generic injectables.

 

Leading Players in the Global Generic Injectables Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

Pfizer Inc.

The global pharmaceutical giant Pfizer has a strong presence in the generic injectables market. Acquired in 2015, its subsidiary Hospira specializes in injectable drugs and infusion technologies.

 

Teva Pharmaceutical Industries Ltd.

Headquartered in Israel, Teva is one of the largest generic drug manufacturers in the world. The company offers a range of generic injectable products in multiple therapeutic areas including pain management and oncology.

 

Baxter

Baxter International Inc. is a global leader in generic injectables, specializing in anesthesia and critical care domain. The company is popular for its innovative delivery systems and premixed injectable drugs.

 

Novartis Pharmaceuticals Corporation

In October 2023, Novartis completed the Spin-off of its generics and biosimilars business, Sandoz, which is a key player in the generic injectables market, focusing on therapeutic areas such as oncology, immunology, and endocrinology.

 

Other players in the market include Fresenius SE & Co. KGaA, Endo, Inc., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sagent Pharmaceuticals, Viatris Inc. (Mylan N.V.), Biocon, Sanofi, Lupin, Aurobindo Pharma Limited, and Sun Pharmaceutical Industries Ltd, among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Container Type
  • Application
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Product Type
  • Large Molecule Injectables
  • Small Molecule Injectables
Breakup by Container Type
  • Vials
  • Premix
  • Prefilled Syringes
  • Ampoules
  • Others
Breakup by Application
  • Oncology
  • Cardiovascular
  • CNS
  • Infectious Diseases
  • Autoimmune Disorders
  • Others
Breakup by Route of Administration
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Others
Breakup by Distribution Channel
  • Hospital
  • Retail Pharmacy
  • Others 
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Baxter.
  • Novartis Pharmaceuticals Corporation
  • Fresenius SE & Co. KGaA
  • Endo, Inc.
  • Hikma Pharmaceuticals PLC
  • Dr.Reddy’s Laboratories Ltd.
  • Sagent Pharmaceuticals
  • Viatris Inc.
  • Biocon
  • Sanofi
  • Lupin.
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Ltd.  

 

Key Questions Answered in the Global Generic Injectables Market Report

  • What was the global generic injectables market value in 2023?
  • What is the global generic injectables market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on product type?
  • What is the market breakup based on container type?
  • What are the major applications areas of generic injectables?
  • What is the market breakup by route of administration?
  • What are the distribution channels in the market?
  • What are the major factors aiding the global generic injectables market demand? 
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints? 
  • Which regional market is expected to lead the market share in the forecast period? 
  • Which country is expected to experience expedited growth during the forecast period? 
  • How do the prevalence and incidence of chronic diseases affect the market landscape?
  • What are the major global generic injectables market trends?
  • How does the rise in the geriatric population impact the market size?
  • Which product type will dominate the market share? 
  • Which application area is expected to have a high market value in the coming years?
  • Which container type will experience the highest demand in the market segment?
  • Which distribution channel will contribute significantly to the market growth?
  • Which route of administration is poised to lead the market share?
  • Who are the key players involved in the generic injectables market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology                  
2    Executive Summary
3     Global Generic Injectables Market Overview 

    3.1     Global Generic Injectables Market Historical Value (2017-2023) 
    3.2     Global Generic Injectables Market Forecast Value (2024-2032)
4     Global Generic Injectables Market Landscape*
    4.1     Global Generic Injectables Market: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2     Global Generic Injectables Market: Product Landscape
        4.2.1    Analysis by Product Type
        4.2.2    Analysis by Cell
        4.2.3    Analysis by Molecule
5    Global Generic Injectables Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6     Global Generic Injectables Market Segmentation (2017-2032)
    6.1     Global Generic Injectables Market (2017-2032) by Product Type
        6.1.1    Market Overview
        6.1.2    Large Molecule Injectables
            6.1.2.1    Monoclonal Antibodies (mAbs)
            6.1.2.2    Insulin
            6.1.2.3    Others
        6.1.3    Small Molecule Injectables
    6.2    Global Generic Injectables Market (2017 - 2032) by Container Type
        6.2.1    Market Overview
        6.2.2    Vials
        6.2.3    Premix
        6.2.4    Prefilled Syringes
        6.2.5    Ampoules
        6.2.6    Others
    6.3    Global Generic Injectables Market (2017-2032) by Application
        6.3.1    Market Overview
        6.3.2    Oncology
        6.3.3    Cardiovascular
        6.3.4    CNS
        6.3.5    Infectious Diseases
        6.3.6    Autoimmune Disorders
        6.3.7    Others
    6.4    Global Generic Injectables Market (2017 - 2032) by Route of Administration
        6.4.1    Market Overview
        6.4.2    Intravenous
        6.4.3    Intramuscular
        6.4.4    Subcutaneous
        6.4.5    Others
    6.5    Global Generic Injectables Market (2017 - 2032) by Distribution Channel
        6.5.1    Market Overview
        6.5.2    Hospital
        6.5.3    Retail Pharmacy
        6.5.4    Others 
    6.6    Global Generic Injectables Market (2017-2032) by Region
        6.6.1    Market Overview
        6.6.2    North America
        6.6.3    Europe 
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Generic Injectables Market (2017-2032)
    7.1    North America Generic Injectables Market (2017-2032) by Product Type
        7.1.1    Market Overview
        7.1.2    Large Molecule Injectables
            7.1.2.1    Monoclonal Antibodies (mAbs)
            7.1.2.2    Insulin
            7.1.2.3    Others
        7.1.3    Small Molecule Injectables
    7.2    North America Generic Injectables Market (2017 - 2032) by Container Type
        7.2.1    Market Overview
        7.2.2    Vials
        7.2.3    Premix
        7.2.4    Prefilled Syringes
        7.2.5    Ampoules
        7.2.6    Others
    7.3    North America Generic Injectables Market (2017-2032) by Application
        7.3.1    Market Overview
        7.3.2    Oncology
        7.3.3    Cardiovascular
        7.3.4    CNS
        7.3.5    Infectious Diseases
        7.3.6    Autoimmune Disorders
        7.3.7    Others
    7.4    North America Generic Injectables Market (2017 - 2032) by Route of Administration
        7.4.1    Market Overview
        7.4.2    Intravenous
        7.4.3    Intramuscular
        7.4.4    Subcutaneous
        7.4.5    Others
    7.5    North America Generic Injectables Market (2017 - 2032) by Distribution Channel
        7.5.1    Market Overview
        7.5.2    Hospital
        7.5.3    Retail Pharmacy
        7.5.4    Others
    7.6    North America Generic Injectables Market (2017-2032) by Country
        7.6.1    United States
        7.6.2    Canada
8    Europe Generic Injectables Market (2017-2032)
    8.1    Europe Generic Injectables Market (2017-2032) by Product Type
        8.1.1    Market Overview
        8.1.2    Large Molecule Injectables
            8.1.2.1    Monoclonal Antibodies (mAbs)
            8.1.2.2    Insulin
            8.1.2.3    Others
        8.1.3    Small Molecule Injectables
    8.2    Europe Generic Injectables Market (2017 - 2032) by Container Type
        8.2.1    Market Overview
        8.2.2    Vials
        8.2.3    Premix
        8.2.4    Prefilled Syringes
        8.2.5    Ampoules
        8.2.6    Others
    8.3    Europe Generic Injectables Market (2017-2032) by Application
        8.3.1    Market Overview
        8.3.2    Oncology
        8.3.3    Cardiovascular
        8.3.4    CNS
        8.3.5    Infectious Diseases
        8.3.6    Autoimmune Disorders
        8.3.7    Others
    8.4    Europe Generic Injectables Market (2017 - 2032) by Route of Administration
        8.4.1    Market Overview
        8.4.2    Intravenous
        8.4.3    Intramuscular
        8.4.4    Subcutaneous
        8.4.5    Others
    8.5    Europe Generic Injectables Market (2017 - 2032) by Distribution Channel
        8.5.1    Market Overview
        8.5.2    Hospital
        8.5.3    Retail Pharmacy
        8.5.4    Others
    8.6    Europe Generic Injectables Market (2017-2032) by Country
        8.6.1    Market Overview
        8.6.2    United Kingdom
        8.6.3    Germany
        8.6.4    France
        8.6.5    Italy
        8.6.6    Others
9     Asia Pacific Generic Injectables Market (2017-2032)
    9.1    Asia Pacific Generic Injectables Market (2017-2032) by Product Type
        9.1.1    Market Overview
        9.1.2    Large Molecule Injectables
            9.1.2.1    Monoclonal Antibodies (mAbs)
            9.1.2.2    Insulin
            9.1.2.3    Others
        9.1.3    Small Molecule Injectables
    9.2    Asia Pacific Generic Injectables Market (2017 - 2032) by Container Type
        9.2.1    Market Overview
        9.2.2    Vials
        9.2.3    Premix
        9.2.4    Prefilled Syringes
        9.2.5    Ampoules
        9.2.6    Others
    9.3    Asia Pacific Generic Injectables Market (2017-2032) by Application
        9.3.1    Market Overview
        9.3.2    Oncology
        9.3.3    Cardiovascular
        9.3.4    CNS
        9.3.5    Infectious Diseases
        9.3.6    Autoimmune Disorders
        9.3.7    Others
    9.4    Asia Pacific Generic Injectables Market (2017 - 2032) by Route of Administration
        9.4.1    Market Overview
        9.4.2    Intravenous
        9.4.3    Intramuscular
        9.4.4    Subcutaneous
        9.4.5    Others
    9.5    Asia Pacific Generic Injectables Market (2017 - 2032) by Distribution Channel
        9.5.1    Market Overview
        9.5.2    Hospital
        9.5.3    Retail Pharmacy
        9.5.4    Others
    9.6    Asia Pacific Generic Injectables Market (2017-2032) by Country
        9.6.1    Market Overview
        9.6.2    China
        9.6.3    Japan
        9.6.4    India
        9.6.5    ASEAN
        9.6.6    Australia
        9.6.7    Others
10    Latin America Generic Injectables Market (2017-2032)
    10.1     Latin America Generic Injectables Market (2017-2032) by Product Type
        10.1.1    Market Overview
        10.1.2    Large Molecule Injectables
            10.1.2.1    Monoclonal Antibodies (mAbs)
            10.1.2.2    Insulin
            10.1.2.3    Others
        10.1.3    Small Molecule Injectables
    10.2     Latin America Generic Injectables Market (2017 - 2032) by Container Type
        10.2.1    Market Overview
        10.2.2    Vials
        10.2.3    Premix
        10.2.4    Prefilled Syringes
        10.2.5    Ampoules
        10.2.6    Others
    10.3     Latin America Generic Injectables Market (2017-2032) by Application
        10.3.1    Market Overview
        10.3.2    Oncology
        10.3.3    Cardiovascular
        10.3.4    CNS
        10.3.5    Infectious Diseases
        10.3.6    Autoimmune Disorders
        10.3.7    Others
    10.4     Latin America Generic Injectables Market (2017 - 2032) by Route of Administration
        10.4.1    Market Overview
        10.4.2    Intravenous
        10.4.3    Intramuscular
        10.4.4    Subcutaneous
        10.4.5    Others
    10.5     Latin America Generic Injectables Market (2017 - 2032) by Distribution Channel
        10.5.1    Market Overview
        10.5.2    Hospital
        10.5.3    Retail Pharmacy
        10.5.4    Others
    10.6     Latin America Generic Injectables Market (2017-2032) by Country
        10.6.1    Market Overview
        10.6.2    Brazil
        10.6.3    Argentina
        10.6.4    Mexico
        10.6.5    Others
11    Middle East and Africa Generic Injectables Market (2017-2032)
    11.1     Middle East and Africa Generic Injectables Market (2017-2032) by Product Type
        11.1.1    Market Overview
        11.1.2    Large Molecule Injectables
            11.1.2.1    Monoclonal Antibodies (mAbs)
            11.1.2.2    Insulin
            11.1.2.3    Others
        11.1.3    Small Molecule Injectables
    11.2     Middle East and Africa Generic Injectables Market (2017 - 2032) by Container Type
        11.2.1    Market Overview
        11.2.2    Vials
        11.2.3    Premix
        11.2.4    Prefilled Syringes
        11.2.5    Ampoules
        11.2.6    Others
    11.3     Middle East and Africa Generic Injectables Market (2017-2032) by Application
        11.3.1    Market Overview
        11.3.2    Oncology
        11.3.3    Cardiovascular
        11.3.4    CNS
        11.3.5    Infectious Diseases
        11.3.6    Autoimmune Disorders
        11.3.7    Others
    11.4     Middle East and Africa Generic Injectables Market (2017 - 2032) by Route of Administration
        11.4.1    Market Overview
        11.4.2    Intravenous
        11.4.3    Intramuscular
        11.4.4    Subcutaneous
        11.4.5    Others
    11.5     Middle East and Africa Generic Injectables Market (2017 - 2032) by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital
        11.5.3    Retail Pharmacy
        11.5.4    Others
    11.6     Middle East and Africa Generic Injectables Market (2017-2032) by Country
        11.6.1    Market Overview
        11.6.2    Saudi Arabia
        11.6.3    United Arab Emirates
        11.6.4    Nigeria
        11.6.5    South Africa
        11.6.6    Others
12    Regulatory Framework
    12.1    Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent Analysis
    13.1      Analysis by Component of Patent
    13.2      Analysis by Publication year
    13.3      Analysis by Issuing Authority
    13.4      Analysis by Patent Age
    13.5      Analysis by CPC Analysis
    13.6      Analysis by Patent Valuation 
    13.7      Analysis by Key Players
14    Grants Analysis
    14.1     Analysis by Year
    14.2     Analysis by Amount Awarded
    14.3     Analysis by Issuing Authority
    14.4     Analysis by Grant Product
    14.5     Analysis by Funding Institute
    14.6     Analysis by Departments
    14.7     Analysis by Recipient Organization 
15    Funding and Investment Analysis
    15.1     Analysis by Funding Instances
    15.2     Analysis by Component of Funding
    15.3     Analysis by Funding Amount
    15.4     Analysis by Leading Players
    15.5     Analysis by Leading Investors
    15.6     Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1     Analysis by Partnership Instances
    16.2     Analysis by Component of Partnership
    16.3     Analysis by Leading Players
    16.4     Analysis by Geography
17    Supplier Landscape
    17.1    Market Share by Top 5 Companies
    17.2    Pfizer Inc.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications 
    17.3    Teva Pharmaceutical Industries Ltd.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Baxter.
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Novartis Pharmaceuticals Corporation
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Fresenius SE & Co. KGaA
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Endo, Inc.
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Hikma Pharmaceuticals PLC
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Dr.Reddy’s Laboratories Ltd.
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Sagent Pharmaceuticals
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Viatris Inc.
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications 
    17.12    Biocon
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications                     
    17.13    Sanofi
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications                 
    17.14    Lupin.
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    Aurobindo Pharma Limited
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
    17.16    Sun Pharmaceutical Industries Ltd.  
        17.16.1    Financial Analysis
        17.16.2    Product Portfolio
        17.16.3    Demographic Reach and Achievements
        17.16.4    Mergers and Acquisitions
        17.16.5    Certifications                      
18    Global Generic Injectables Market – Distribution Model (Additional Insight)
    18.1     Overview 
    18.2     Potential Distributors 
    18.3     Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1     Very Small Companies
    20.2     Small Companies
    20.3     Mid-Sized Companies
    20.4     Large Companies
    20.5     Very Large Companies
21    Payment Methods (Additional Insight)
    21.1     Government Funded
    21.2     Private Insurance
    21.3     Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER